Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Penpulimab in combination with chemotherapy or anlotinib for metastatic nonsquamous NSCLC
NCT03866980Phase 3Terminated
- Sponsor
- Akeso, Inc.
- Start
- Nov 2018
- Primary completion
- Jun 2023
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 3 trial of penpulimab in Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC), sponsored by Akeso, Inc.. Started Nov 2018; status: terminated.
02
Drugs
penpulimab
03
Conditions
Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC)
Beyond the preview
Go deeper on NCT03866980.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03866980.